Sandbox g12: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) mNo edit summary |
||
| Line 24: | Line 24: | ||
:* '''Drugs with conditional TdP risk''' | :* '''Drugs with conditional TdP risk''' | ||
::* [[ | ::* [[Albuterol (salbutamol)|Albuterol (salbutamol) (Proventil®, Ventolin®, Ventolin-HFA®, Accuneb®, Combivent®, Vospire-ER®, ProAir HFA®, Duoneb®)]] | ||
::* [[ | ::* [[Haloperidol|Haloperidol (Haldol® (US & UK), Aloperidin®, Bioperidolo®, Brotopon®, Dozic®, Duraperidol® (Germany), Einalon S®, Eukystol®, Halosten®, Keselan®, Linton®, Peluces®, Serenace®, Serenase®, Sigaperidol®)]] | ||
::* [[ | ::* [[Isoproterenol|Isoproterenol (Medihaler-Iso®, Isuprel®)]] | ||
::* [[Itraconazole|Itraconazole (Sporanox®, Onmel®)]] | |||
::* [[Methylphenidate|Methylphenidate (Ritalin®, Concerta®, Focalin®, Daytrana®, Methylin®, Metadate CD®)]] | |||
::* [[Moexipril/HCTZ|Moexipril/HCTZ (Uniretic®, Univasc®)]] | |||
::* [[Pimozide|Pimozide (Orap®)]] | |||
::* [[Quetiapine|Quetiapine (Seroquel®)]] | |||
::* [[Risperidone|Risperidone (Risperdal®)]] | |||
::* [[Tacrolimus|Tacrolimus (Prograf®, Prograf®, Advagraf®, Protopic®)]] | |||
::* [[Vemurafenib|Vemurafenib (Zelboraf®)]] | |||
:* '''Drugs to be avoided by congenital Long QT''' | :* '''Drugs to be avoided by congenital Long QT''' | ||
Revision as of 21:41, 31 May 2015
- Risk categories for antimicrobial agents known to have an association with TdP[1]
- Drugs with known TdP risk
- Azithromycin (Zithromax®, Zmax®)
- Chloroquine (Aralen®)
- Ciprofloxacin (Cipro®, Cipro-XR®, Neofloxin®)
- Clarithromycin (Biaxin®, Prevpac®)
- Erythromycin (A/T/S®, Akne-Mycin®, Emgel®, Ery-Tab®, Eryc®, Erycette®, Eryderm®, Erygel®)
- Halofantrine (Halfan®)
- Levofloxacin (Levaquin®, Tavanic®)
- Moxifloxacin (Avelox®, Avalox®, Avelon®)
- Pentamidine (Pentam®)
- Sparfloxacin (Zagam®)
- Drugs with possible TdP risk
- Bedaquiline (Sirturo®)
- Dihydroartemisinin-Piperaquine (Eurartesim®)
- Gatifloxacin (Tequin®)
- Gemifloxacin (Factive®)
- Norfloxacin (Noroxin®, Ambigram®)
- Ofloxacin (Floxin®)
- Roxithromycin (Rulide®, Xthrocin®, Roxl-150®, Roxo®, Surlid®, Rulide®, Biaxsig®, Roxar®, Roximycinv®, Roxomycin®, Rulid®, Tirabicin®, Coroxin®)
- Telavancin (Vibativ®)
- Telithromycin (Ketek®)
- Drugs with conditional TdP risk
- Albuterol (salbutamol) (Proventil®, Ventolin®, Ventolin-HFA®, Accuneb®, Combivent®, Vospire-ER®, ProAir HFA®, Duoneb®)
- Haloperidol (Haldol® (US & UK), Aloperidin®, Bioperidolo®, Brotopon®, Dozic®, Duraperidol® (Germany), Einalon S®, Eukystol®, Halosten®, Keselan®, Linton®, Peluces®, Serenace®, Serenase®, Sigaperidol®)
- Isoproterenol (Medihaler-Iso®, Isuprel®)
- Itraconazole (Sporanox®, Onmel®)
- Methylphenidate (Ritalin®, Concerta®, Focalin®, Daytrana®, Methylin®, Metadate CD®)
- Moexipril/HCTZ (Uniretic®, Univasc®)
- Pimozide (Orap®)
- Quetiapine (Seroquel®)
- Risperidone (Risperdal®)
- Tacrolimus (Prograf®, Prograf®, Advagraf®, Protopic®)
- Vemurafenib (Zelboraf®)
- Drugs to be avoided by congenital Long QT
- Torsades de pointes risk stratification schedules for antimicrobial agents[2]
- Schedule I (Highest TdP risk, potent IKr blockers, TdP risk >1%)
- Not available
- Schedule II (Significant risk for TdP, particularly when coadministered with CYP inhibitors, relatively potent IKr blockade)
- Not available
- Schedule III (Risk for TdP is described, IKr blockade, particularly when coadministered with CYP inhibitors)
- Schedule IV (Minimal risk for TdP, case reports of TdP, mild IKr blockade, may have CYP interactions)
- Schedule V (Questionable/minimal risk for QT interval prolongation/TdP)